KR20240134887A - 아자인돌 유도체 및 erk 키나제 억제제로서의 그의 용도 - Google Patents

아자인돌 유도체 및 erk 키나제 억제제로서의 그의 용도 Download PDF

Info

Publication number
KR20240134887A
KR20240134887A KR1020247023085A KR20247023085A KR20240134887A KR 20240134887 A KR20240134887 A KR 20240134887A KR 1020247023085 A KR1020247023085 A KR 1020247023085A KR 20247023085 A KR20247023085 A KR 20247023085A KR 20240134887 A KR20240134887 A KR 20240134887A
Authority
KR
South Korea
Prior art keywords
pyridin
atom
ethyl
compound
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247023085A
Other languages
English (en)
Korean (ko)
Inventor
씨드릭 보리
로익 마티유
장-프랑수아 기슈
뮤리엘 겔랑
오렐리앙 비에쉬
Original Assignee
에이지브이 디스커버리
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)
상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄
유니베르시테 드 몽펠리에
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이지브이 디스커버리, 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸), 상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄, 유니베르시테 드 몽펠리에 filed Critical 에이지브이 디스커버리
Publication of KR20240134887A publication Critical patent/KR20240134887A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020247023085A 2022-01-14 2023-01-13 아자인돌 유도체 및 erk 키나제 억제제로서의 그의 용도 Pending KR20240134887A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305031.1A EP4212531A1 (en) 2022-01-14 2022-01-14 Azaindole derivatives and their use as erk kinase inhibitors
EP22305031.1 2022-01-14
PCT/EP2023/050692 WO2023135233A1 (en) 2022-01-14 2023-01-13 Azaindole derivatives and their use as erk kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20240134887A true KR20240134887A (ko) 2024-09-10

Family

ID=80445694

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247023085A Pending KR20240134887A (ko) 2022-01-14 2023-01-13 아자인돌 유도체 및 erk 키나제 억제제로서의 그의 용도

Country Status (16)

Country Link
US (3) US11827637B2 (https=)
EP (2) EP4212531A1 (https=)
JP (1) JP2025502377A (https=)
KR (1) KR20240134887A (https=)
CN (1) CN118541370A (https=)
AR (1) AR128267A1 (https=)
AU (1) AU2023207276A1 (https=)
CA (1) CA3242894A1 (https=)
CL (1) CL2024002070A1 (https=)
CO (1) CO2024008809A2 (https=)
IL (1) IL314199A (https=)
JO (1) JOP20240157A1 (https=)
MX (1) MX2024008629A (https=)
TW (1) TW202334147A (https=)
UA (1) UA130477C2 (https=)
WO (1) WO2023135233A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2025012386A1 (en) * 2023-07-12 2025-01-16 Agv Discovery Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor
WO2025012357A1 (en) * 2023-07-12 2025-01-16 Ipsen Pharma Fluorinated azaindole derivatives and their use as erk kinase inhibitors
CN121511244A (zh) * 2023-07-12 2026-02-10 Agv探索公司 (s)-1-(1-(3-氯苯基)-2-(二甲氨基)乙基)-4-(5-吗啉代-1h-吡咯并[2,3-b]吡啶-3-基)吡啶-2(1h)-酮的盐，其制备及其作为erk激酶抑制剂的用途
EP4588918A1 (en) 2024-01-18 2025-07-23 AGV Discovery Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one
WO2026064271A1 (en) 2024-09-23 2026-03-26 Fmc Corporation Substituted bicyclic amide derivatives as herbicides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
UA84930C2 (ru) 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN100396678C (zh) 2004-11-16 2008-06-25 财团法人工业技术研究院 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
WO2012094313A1 (en) 2011-01-04 2012-07-12 Kinentia Biosciences Llc Pyrazole derivatives as erk inhibitors
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
EP3247353A4 (en) 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
BR112021009430A2 (pt) * 2018-11-16 2021-08-17 California Institute Of Technology inibidores de erk e usos dos mesmos
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Also Published As

Publication number Publication date
US12421231B2 (en) 2025-09-23
UA130477C2 (uk) 2026-02-25
WO2023135233A1 (en) 2023-07-20
JP2025502377A (ja) 2025-01-24
TW202334147A (zh) 2023-09-01
CO2024008809A2 (es) 2024-08-08
CN118541370A (zh) 2024-08-23
AU2023207276A1 (en) 2024-08-01
AR128267A1 (es) 2024-04-10
EP4212531A1 (en) 2023-07-19
US11827637B2 (en) 2023-11-28
US20260042758A1 (en) 2026-02-12
US20230227451A1 (en) 2023-07-20
IL314199A (en) 2024-09-01
US20240308997A1 (en) 2024-09-19
EP4463453A1 (en) 2024-11-20
CA3242894A1 (en) 2025-02-28
CL2024002070A1 (es) 2024-11-29
MX2024008629A (es) 2024-08-19
JOP20240157A1 (ar) 2024-07-14

Similar Documents

Publication Publication Date Title
US12421231B2 (en) Azaindole derivatives and their use as ERK kinase inhibitors
EP4263545B1 (en) Prmt5 inhibitors
JP7738619B2 (ja) Ｅｒｂｂ／ｂｔｋ阻害剤
JP2022517723A (ja) Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
AU2015335703B2 (en) Carbazole derivatives
KR102912166B1 (ko) 단백질 키나아제 억제제로서의 퀴놀린 유도체
JP2016517412A (ja) Ｆａｓｎを阻害するための新規化合物および組成物
JP2020522465A (ja) Ｐｌｋ１阻害剤としてのピロール誘導体
WO2024149275A1 (zh) Kras抑制剂化合物
EA050871B1 (ru) Производные азаиндола и их применение в качестве ингибиторов киназы erk
EP4367123A1 (en) Pyrimidine compounds for use as map4k1 inhibitors
HK40108291A (zh) 氮杂吲哚衍生物及其作为erk激酶抑制剂的用途
AU2019278104B2 (en) JAK3 selective inhibitor
WO2025012386A1 (en) Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor
WO2025012357A1 (en) Fluorinated azaindole derivatives and their use as erk kinase inhibitors
WO2025012383A1 (en) Azaindole derivatives with a cyclo(hetero)aliphatic ring and their use as erk kinase inhibitors
TW202604504A (zh) 含氮並環化合物、含其的藥物組合物及其應用
CN118103366A (zh) 作为glp-1受体调节剂的某些2,5-二氮杂双环[4.2.0]辛烷
KR102096679B1 (ko) 화합물의 제조를 위한 중간체 및 방법
CN121419973A (zh) Malt1抑制剂
CA3245417A1 (en) COMPOUND USED AS A TYK2 INHIBITOR, ITS PREPARATION PROCESS AND PHARMACEUTICAL USE

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000